TCRX earnings
TScan Therapeutics Inc. (TCRX) earnings releases and earnings dates - real-time wire coverage of every quarterly report.
Recent earnings items
- TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027Positive end of Phase I meeting and agreement reached with FDA on pivotal study design for TSC-101 Dosed first solid tumor patients with multiplex TCR-T therapy; paused further enrollment to prioritize heme development; reiterates planned data readout in Q1 2026 Enacted ~30% workforce reduction to focus clinical development on heme program and initiate pre-clinical development of in vivo-engineered TCR-T for solid tumors Strategic prioritization extends cash runway into H2 2027 Conference call and webcast scheduled for Monday, November 3, 8:00 a.m. Eastern Time WALTHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology comp
- TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTRAll eight (100%) treatment-arm patients are relapse-free and have achieved and maintained complete donor chimerism following treatment with TSC-100 or TSC-101 Patient with high-risk, TP53-mutated MDS is relapse-free for over one year following treatment with TSC-101 Patient with AML converted from detectable to undetectable disease following treatment with TSC-101 Data presented at TANDEM meeting suggests complete donor chimerism is an early indicator of treatment success Company to host virtual KOL event today, Monday, February 26, at 8:00 a.m. ET, to discuss the data presented at the 2024 Tandem Meetings WALTHAM, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- TScan Th
- TScan Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent ProgressPhase 1 umbrella trial for hematologic malignancies open for enrollment Publication in Cell further validates use of foundational technology to identify novel tumor antigens and effective TCRs TSC-200-A2 (HPV) and TSC-204-C7 (MAGE-A1) IND filings anticipated by year-end 2022 Appointment of Debora Barton, M.D., as Chief Medical Officer Ended quarter with cash and cash equivalents of $125.6 million, funding operations into 2024 WALTHAM, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer,